Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
12/1993
12/09/1993WO1993024449A1 Peptidyl derivatives and their use as metalloproteinases inhibitors
12/09/1993WO1993024448A1 Amino acid derivative and use thereof
12/09/1993WO1993024142A1 New pharmaceutical uses of krill enzymes
12/09/1993WO1993024096A2 Use of n-(2-(dimethylamino)ethyl)acridine-4-carboxamide and its analogues for cancer treatment
12/09/1993WO1992021344A3 Modulation of cellular response to external stimuli
12/09/1993CA2306952A1 Method for removing dental plaque
12/09/1993CA2136860A1 Use of n-(2-(dimethylamino)ethyl)acridine-4-carboxamide and its analogues for cancer treatment
12/09/1993CA2136624A1 Peptides of human p53 protein for use in human t cell response inducing compositions, and human p53 protein-specific cytotoxic t-lymphocytes
12/09/1993CA2136428A1 Peptide inhibitors of selectin binding
12/09/1993CA2135394A1 Desferrioxamine-b salts and their use as orally effective iron chelators
12/09/1993CA2134773A1 Methods and compositions for in vivo gene therapy
12/09/1993CA2114623A1 Sulphamide derivatives as metalloproteinase inhibitors
12/09/1993CA2114622A1 Peptidyl derivatives and their use as metalloproteinases inhibitors
12/08/1993EP0573133A1 Means for transdermal application of Gestoden
12/08/1993EP0572922A1 Synergistic combinations comprising lipoic acid and vitamines in medicaments
12/08/1993EP0572563A1 Treatment of esophageal cancer
12/08/1993EP0572557A1 Treatment of ovarian cancer
12/08/1993EP0572549A1 Treatment of non-small cell lung carcinoma
12/08/1993EP0572505A1 Human platelet-derived growth factor receptors
12/08/1993EP0572470A1 Process for producing a medical composition with a bone marrow protective effect and an anti-neoplastic effect
12/08/1993EP0409858B1 Heparin-binding proteins, dna coding for them, processes for producing them as well as therapeutic preparations containing them
12/08/1993CN1079225A Tnf-muteins
12/08/1993CN1079215A Morpholinyl derivatives of doxorubicin and process for their preparation
12/07/1993US5268467 Immunomodulatory polysaccharide fractions from Astragalus plants
12/07/1993US5268364 Block addition of a serine or threonine residue to protein
12/07/1993CA2095944A1 Azole derivatives and antimycotic and antiaromatase agents containing them
12/07/1993CA1324954C Inhibition of cell migration with synthetic peptides
12/06/1993CA2097731A1 Antitumoral compounds
12/02/1993DE4217964A1 Indolocarbazol-Imide und deren Verwendung Indolocarbazole imides and the use thereof
12/01/1993EP0572287A2 Use of cyclic double-stranded oligonucleotides containing the binding site for a transcription factor for inhibiting gene expression
12/01/1993EP0572109A1 Halichondrins: Cytotoxic polyether macrolides
12/01/1993EP0571546A1 Chroman and thiochromans with phenylethynyl substituents at the 7-position having retinoid-like biological activity.
12/01/1993EP0571387A1 A non-mitogenic competitive hgf antagonist
12/01/1993EP0487591B1 Anticoagulant protein
11/1993
11/30/1993US5266600 Also for treatment of AIDS
11/30/1993US5266576 N-myristoyl transferase inhibitors
11/30/1993US5266575 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
11/30/1993US5266318 Synergistic wound healing mixture with allantoin
11/25/1993WO1993023572A1 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
11/25/1993WO1993023569A1 Method and reagent for inhibiting viral replication
11/25/1993WO1993023557A1 Anti-receptor agents to the vitamin b12/transcobalamin ii receptor
11/25/1993WO1993023555A1 Cultured taxus tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
11/25/1993WO1993023549A2 Nucleic acid corresponding to a gene of chromosome 22 involved in recurrent chromosomal translocations associated with the development of cancerous tumors
11/25/1993WO1993023546A1 Methods and compositions for increasing the sensitivity of a cell to a dna damaging agent
11/25/1993WO1993023429A1 Receptor-type tyrosine kinase-like molecules
11/25/1993WO1993023424A1 Derivatives of dolastatin
11/25/1993WO1993023389A1 Novel taxane derivatives, their preparation and compositions containing same
11/25/1993WO1993023375A1 Substituted pyridines, their preparation and pharmaceutical use
11/25/1993WO1993023079A1 Method for nonspecific cellular immune stimulation
11/25/1993WO1993023069A1 Health supplements containing phyto-oestrogens, analogues or metabolites thereof
11/25/1993WO1993023067A1 Igf-1 analogs
11/25/1993WO1993023062A1 Therapeutic conjugates of toxins and drugs
11/25/1993WO1993023058A1 Use of 2-halo adenine derivatives as therapeutic agents against chronic myelogenous leukemia
11/25/1993WO1993023053A1 INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY
11/25/1993WO1993023046A1 Enantiomeric cynemicin analogs, preparation and use thereof
11/25/1993WO1993023034A1 Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy
11/25/1993WO1993023014A1 Chemotherapeutic drug combinations
11/25/1993WO1993017684A3 Enantiomeric hydroxylated xanthine compounds
11/25/1993DE4216829A1 Pyridyl derivs. with antithrombotic properties
11/25/1993DE4216364A1 Pyridyl derivs. with antithrombotic properties
11/25/1993CA2136304A1 Inhibitors of testosterone 5.alpha.-reductase activity
11/25/1993CA2136234A1 Enantiomeric dynemicin analogs, preparation and use thereof
11/25/1993CA2136213A1 Cultured taxu tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
11/25/1993CA2136211A1 Novel taxane derivatives, their preparation and compositions containing same
11/25/1993CA2136091A1 Chemotherapeutic drug combinations
11/25/1993CA2135784A1 Method for nonspecific cellular immune stimulation
11/25/1993CA2135646A1 Method and reagent for inhibiting viral replication
11/25/1993CA2135471A1 Receptor-type tyrosine kinase-like molecules
11/25/1993CA2135306A1 Igf-1 analogs
11/25/1993CA2134563A1 Substituted pyridines, their preparation and pharmaceutical use
11/24/1993EP0571267A1 Use of azole derivatives for the preparation of drugs useful for inhibiting the aromatase and treating of estrogen-dependent diseases
11/24/1993EP0570519A1 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
11/24/1993EP0570514A1 Methylene phosphonate nucleoside analogs and oligonucleotide analogs made therefrom
11/24/1993EP0570475A1 Pharmaceutical preparation for the therapy of tumors, particularly ovarian and haemopoietic system tumors, containing quercetin compounds as active substances
11/23/1993US5264591 Baccatine III derivatives
11/23/1993US5264578 Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
11/23/1993US5264431 Inhibitors for proteinkinase C
11/23/1993US5264221 Liposomes with maleimide groups bonded to thiol groups in proteins for antitumor agents
11/23/1993CA1324611C Process for the preparation of taxol
11/22/1993CA2091709A1 Method for inhibiting aromatase
11/21/1993CA2096196A1 Pharmaceutical compositions
11/18/1993EP0570294A1 2-Formylpyridine thiosemicarbazone derivatives, their preparation and their use as antitumor agents
11/18/1993EP0570091A1 Anthraquinone derivatives, process for their preparation and their use as medicaments
11/18/1993EP0570022A2 Chelants possessing ortho ligating functionality and complexes thereof
11/18/1993EP0569583A1 Controlled use of polyether-substituted tumor agents in diagnosis and therapy
11/18/1993EP0569507A1 Derivatives of porphycene of direct utility in photodynamic therapy or as intermediates for synthesis of photoactivatable dyes suitable for photodynamic therapy
11/18/1993EP0331743B1 Protein derived from living body
11/18/1993EP0313569B1 Enhancement of the cellular immune response
11/17/1993CN1078401A Immunotoxins directed against CD33 related surface antigens
11/17/1993CN1078388A Treatment of disease employing hyuluronic acid and NSAIDS
11/16/1993US5262440 Antitumor compositions and methods of treatment
11/16/1993US5262425 α-mannosidase inhibitors
11/16/1993US5262319 Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
11/16/1993CA1324383C Process for the manufacture of novel substituted aminomethanediphosphonic acids
11/15/1993CA2095404A1 Purification and characterization of a csvtcg-specific tumor cell adhesion receptor
11/11/1993WO1993022449A1 Inhibitory factor
11/11/1993WO1993022437A1 New polypeptides and peptides, nucleic acids coding for them, and their use in the field of tumor therapy, inflammation or immunology
11/11/1993WO1993022431A1 Constitutive and inducible epidermal vector systems
11/11/1993WO1993022430A1 Development of a vector to target gene expression to the epidermis of transgenic animals
11/11/1993WO1993022424A1 RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
1 ... 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 ... 2211